A first study, carried out to check the effect of gefitinib on ErbB receptor signaling pathway in human melanoma cell lines, showed cell cycle arrest in G0/G1 phase and inhibition of cell growth shuting down PI3K/AKT, Jak/Stat, and MAPK signaling pathways (Table 6) [114]. The gene discussed is AKT1; the disease is melanoma.